Literature DB >> 25477563

Paclitaxel, Carboplatin, and trastuzumab.

Jennifer Lee1, Dominic A Solimando1, J Aubrey Waddell1.   

Abstract

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

Entities:  

Year:  2014        PMID： 25477563      PMCID： PMC4252214          DOI： 10.1310/hpj4910-913

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  32 in total

Review 1.  Pathophysiology, severity, pattern, and risk factors for carboplatin-induced emesis.

Authors:  A du Bois; W Vach; M Kiechle; U Cramer-Giraud; H G Meerpohl
Journal:  Oncology       Date:  1996-06       Impact factor: 2.935

2.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

3.  Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

Authors:  Edith A Perez; Vera J Suman; Kendrith M Rowland; James N Ingle; Muhammad Salim; Charles L Loprinzi; Patrick J Flynn; James A Mailliard; Carl G Kardinal; James E Krook; Abby R Thrower; Daniel W Visscher; Robert B Jenkins
Journal:  Clin Breast Cancer       Date:  2005-12       Impact factor: 3.225

4.  Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer.

Authors:  David Loesch; Nicholas Robert; Lina Asmar; Mary Ann Gregurich; Mark O'Rourke; Shaker Dakhil; Edwin Cox
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

5.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Authors:  M D Pegram; A Lipton; D F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; D J Slamon
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

6.  Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

Authors:  Corine Ekhart; Sjoerd Rodenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Cancer Chemother Pharmacol       Date:  2008-11-07       Impact factor: 3.333

7.  A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.

Authors:  G Fountzilas; U Dafni; M A Dimopoulos; A Koutras; D Skarlos; P Papakostas; H Gogas; D Bafaloukos; A Kalogera-Fountzila; E Samantas; E Briasoulis; D Pectasides; N Maniadakis; F Matsiakou; G Aravantinos; C Papadimitriou; M Karina; C Christodoulou; P Kosmidis; H P Kalofonos
Journal:  Breast Cancer Res Treat       Date:  2008-05-16       Impact factor: 4.872

8.  Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.

Authors:  Ke-Da Yu; Guang-Yu Liu; Can-Ming Chen; Jian-Wei Li; Jiong Wu; Jin-Song Lu; Zhen-Zhou Shen; Zhi-Ming Shao
Journal:  Oncologist       Date:  2013-05-01

9.  Hypersensitivity reactions from taxol.

Authors:  R B Weiss; R C Donehower; P H Wiernik; T Ohnuma; R J Gralla; D L Trump; J R Baker; D A Van Echo; D D Von Hoff; B Leyland-Jones
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

10.  Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.

Authors:  Dieter Kaag
Journal:  Lung Cancer       Date:  2012-11-04       Impact factor: 5.705
View more
  1 in total

1.  Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients.

Authors:  Jihong Guo; Qing Li; Pin Zhang; Peng Yuan; Jiayu Wang; Fei Ma; Ying Fan; Ruigang Cai; Yang Luo; Qiao Li; Binghe Xu
Journal:  Chin J Cancer Res       Date:  2019-10       Impact factor: 5.087
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.